Reports Q2 revenue $654.8M, consensus $638.3M. “Astrana Health’s (ASTH) strong second quarter results underscore the power of our physician-focused, technology-enabled model to drive profitable growth and deliver better outcomes at scale,” said Brandon Sim, CEO. “Our unique ability to build longitudinal relationships with our patients, paired with leading clinical capabilities and a purpose-built technology platform affording us real-time visibility of our patients’ health, allows us to operate from a position of strength in a complex and evolving healthcare landscape. As we look ahead, we remain focused on disciplined execution and expanding access to high-quality, coordinated care for the patients and communities we serve.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health price target lowered to $50 from $70 at BTIG
- Astrana Health’s Strategic Acquisition and Financial Guidance Boost: Analyst Recommends Buy
- Astrana Health Completes Acquisition of Prospect Health
- Astrana Health management to meet with Truist
- Astrana Health Approves 2024 Equity Incentive Plan